Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer

INTRODUCTION: PD-(L)1 inhibitors have improved prognosis of non-small-cell lung cancer (NSCLC), but can also cause immune-related adverse events (irAEs) that complicate management. METHODS: We analyzed NSCLC patients receiving PD-(L)1 inhibitors from 2012 to 2020 in a German academic center. RESULTS...

Descripción completa

Detalles Bibliográficos
Autores principales: Daniello, Lea, Elshiaty, Mariam, Bozorgmehr, Farastuk, Kuon, Jonas, Kazdal, Daniel, Schindler, Hannah, Shah, Rajiv, Volckmar, Anna-Lena, Lusky, Fabienne, Diekmann, Leonore, Liersch, Stephan, Faehling, Martin, Muley, Thomas, Kriegsmann, Mark, Benesova, Karolina, Stenzinger, Albrecht, Thomas, Michael, Christopoulos, Petros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277237/
https://www.ncbi.nlm.nih.gov/pubmed/34268127
http://dx.doi.org/10.3389/fonc.2021.703893

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277237/
https://www.ncbi.nlm.nih.gov/pubmed/34268127
http://dx.doi.org/10.3389/fonc.2021.703893

Ejemplares similares